P3781
Open Label Study of Pharmacokinetics and Safety of Dose of Adefovir Dipivoxil in Children and Adolescents With HBVPK Study of Tacrolimus and Cyclosporine When Co-Administered With Adefovir Dipivoxil in Post-Liver Transplant PatientsA Double-Blind Randomized Clinical Trial Comparing the Safety and Antiviral Activity of 48-week Clevudine and Adefovir Dipivoxil in HBeAg(-) Chronic Hepatitis B With Compensated Liver FunctionProspective Exploratory Study to Describe Hepatitis B Virus (HBV) Kinetics During Treatment With TelbivudineEfficacy and Safety of Clevudine Compared With Adefovir in Patients With Chronic Hepatitis Due to Hepatitis B VirusEfficacy and Safety of Clevudine Compared With Adefovir in Patients With HBeAg Positive Chronic Hepatitis Due to Hepatitis B VirusA Randomized Study Comparing Lamivudine Versus Adefovir Dipivoxil for Prevention of zHBV Reactivation in HBsAg Seropositive Patients Undergoing Cytotoxic ChemotherapyA Phase III Study in Post-operative HBV-related Hepatocellular CarcinomaPegIntron Versus Adefovir in the Treatment of Chronic Hepatitis B (CHB) e Antigen Positive Patients in Taiwan (P04498/MK-4031-278)Phase I Study to Investigate the Safety and Efficacy of HBV DNA VaccineTelbivudine Versus Adefovir Dipivoxil in Adults With HBegAg-Positive, Compensated Chronic Hepatitis BTenofovir Monotherapy in Patients With Chronic Hepatitis B Patients Who Had Achieved Complete Viral Suppression on Lamivudine Plus AdefovirA Two-year Study of Telbivudine in HBeAg Negative HepatitisSwitch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B PatientsLamivudine and Adefovir Dipivoxil Fixed Dose CombinationEfficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) 300mg in Chinese Subjects With Chronic Hepatitis B (CHB)HEPSERA Post Marketing SurveillanceDrug-Drug Interaction Study of Vadadustat With Digoxin, Adefovir and Furosemide
P4844
Selective inhibition of anthrax edema factor by adefovir, a drug for chronic hepatitis B virus infectionLamivudine/Adefovir Treatment Increases the Rate of Spontaneous Mutation of Hepatitis B Virus in PatientsTenofovir and adefovir down-regulate mitochondrial chaperone TRAP1 and succinate dehydrogenase subunit B to metabolically reprogram glucose metabolism and induce nephrotoxicityEffect of nonalcoholic steatohepatitis on renal filtration and secretion of adefovir.Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro.Comparison of the Efficacies and Safety of Combined Therapy between Telbivudine Plus Adefovir and Lamivudine Plus Adefovir in Patients with Hepatitis B Virus Infection in Real-World PracticeDe novo entecavir+adefovir dipivoxil+lamivudine triple-resistance mutations resulting from sequential therapy with adefovir dipivoxil, and lamivudine.Effect of adefovir dipivoxil on T cell immune function in the treatment of chronic hepatitis B and hepatocirrhosisComparison of the clinical outcomes between antiviral-naïve patients treated with entecavir and lamivudine-resistant patients receiving adefovir add-on lamivudine combination treatment.Bone Histology of Two Cases with Osteomalacia Related to Low-dose Adefovir.Adefovir dipivoxil-induced Fanconi syndrome and its predictive factors: A study of 28 cases.Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study).Switch to tenofovir-based therapy or to continue adefovir-based therapy in CHB patients with suboptimal response to adefovir-based combination?Relationship between nephrotoxicity and long-term adefovir dipivoxil therapy for chronic hepatitis B: A meta-analysis.Tenofovir disoproxil fumarate monotherapy maintains HBV suppression achieved by a "de novo" combination of lamivudine-adefovir: a pilot study.Tenofovir disoproxil fumarate monotherapy is superior to entecavir-adefovir combination therapy in patients with suboptimal response to lamivudine-adefovir therapy for nucleoside-resistant HBV: a 96-week prospective multicenter trial.Evolutionary trends of resistance mutational patterns of HBV reverse transcriptase over years (2002-2012) of different treatment regimens: The legacy of lamivudine/adefovir combination treatment.Circulating kidney injury molecule-1 is a novel diagnostic biomarker for renal dysfunction during long-term adefovir therapy in chronic hepatitis B.In vitro evaluation of 9-(2-phosphonylmethoxyethyl)adenine ester analogues, a series of anti-HBV structures with improved plasma stability and liver release.Inhibitory effect of adefovir and lamivudine on the initiation of hepatitis B virus infection in primary tupaia hepatocytes.Adefovir dipivoxil therapy in liver transplant recipients with lamivudine-resistant hepatitis B virus.Osteomalacia induced by long-term low-dose adefovir dipivoxil: Clinical characteristics and genetic predictors.Hypophosphatemia predicts a failure to recover from adefovir-related renal injury after dose reduction in lamivudine-resistant hepatitis B patients.Entecavir monotherapy versus de novo combination of lamivudine and adefovir for compensated hepatitis B virus-related cirrhosis: a real-world prospective multicenter cohort studyAn improved synthesis of adefovir and related analoguesViral quasispecies of hepatitis B virus in patients with YMDD mutation and lamivudine resistance may not predict the efficacy of lamivudine/adefovir rescue therapyImproved and simplified liquid chromatographic assay for adefovir, a novel antiviral drug, in human plasma using derivatization with chloroacetaldehydeExtent of intramolecular π-stacks in aqueous solution in mixed-ligand copper(II) complexes formed by heteroaromatic amines and several 2-aminopurine derivatives of the antivirally active nucleotide analog 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA)
P921
Q61914442-86CE5274-0C05-4805-BBD9-DE68299065B4Q61914496-4AF4618E-3F6A-457C-A6E8-1F56ED3B9449Q61914858-CCB88465-08B0-4AD7-B743-4B202A2A37BFQ61914910-268B54ED-E530-4CF2-BE05-FB5984C2C265Q61917509-E40B7DF2-5668-404B-BE89-045FAB1AD904Q61917524-F15E5BE1-512C-4619-9ACB-9B7047AE668FQ61918171-C46C64CD-0705-403B-8933-52AD01D1291CQ61920658-8EF58F63-C3E6-49B7-BCA5-8373E84C5A20Q61933098-2677AF2B-E660-42D4-92DC-49644BE8D8BCQ61978921-143100A8-A664-4C6D-A6A3-96BE069340F4Q62104783-F06C6C78-8CDB-4904-BBC0-AB00070C0B51Q63011202-5987858A-7470-4201-A61D-8001EEF642F1Q63319933-8DFCC6F8-FDDF-42AB-B0E4-361AB0E2AE06Q63320564-3C9DFDB4-361A-4587-80AE-7DCF3493FCBDQ63337800-B58E3C96-BCD6-4C73-B429-AD3B4CAE3248Q63338241-AFC7D623-42D7-4A76-9700-CD8800EF6CE4Q63338288-EC718318-7D39-41AA-8A18-7A8B1236BFA2Q63591472-D788E50E-1E96-4C9B-ACA2-69D1AEB36C45
P4844
Q24311064-2F15A4A6-75F5-471C-8909-D0594D850C0AQ27468616-09A663C0-33AA-4790-ADEF-0A76F54A0378Q33551834-D86452CA-F7AB-4594-A456-8968BC2628EDQ33570726-D064EE3F-7F4F-42A7-A2A6-726DC24A9029Q34105204-0A2D9BF1-DAB8-48BB-B262-C65DABF5502BQ36180446-F1530220-FE5E-4F42-8C30-2D6362738267Q36800501-ADC39575-D7C0-4493-BD7F-ECAC17BBB381Q37288061-746086B7-4DAA-4EB9-A101-C89CB064A932Q37343288-2097138E-94C9-4F87-B796-5D7FF20DA971Q37414389-AC4EADCE-5A82-49EF-AF54-0918E2CB1CF6Q37593985-D6D14EB0-1915-47D5-A2C5-78813E4444ADQ37606534-C83A88A2-25CF-433F-B777-1618BF74CAFCQ37606550-3EE4CC07-DD7B-4658-9FE8-F20DB5D8D31CQ37608351-ACF0E98C-D116-42AF-A246-DB90FAF4929AQ39067389-3CB9D58A-1AB3-4D14-90F9-358F3F4BBEB3Q40230593-36C9075B-9372-429B-8E2B-699D69B8D40AQ40283038-8A81D90B-B853-458F-AD7E-2C4C1EAFFFD5Q40446757-68CA5A64-863F-4AF7-ACFD-59DE9BA8655CQ42249059-FBF4980A-433A-40FF-9FB1-5B1964F38694Q44675028-3E54C428-2EA0-4F47-A5A2-8FC406E650E1Q45471405-E05E4A88-5C10-41EA-84E0-02274FAFEDD0Q51467080-5AF1CFC5-14AF-4F0E-B57F-D5996A6096AFQ53580636-2C5AD1C0-B580-4C75-95A4-C9B3C5E5BC96Q64093388-15C4A8A9-E84A-46E7-A0DB-56F60762D545Q64100797-BE23E456-9BDD-4FCF-AE7E-BBC096DB1429Q64271208-7B04C262-BCCC-4FF8-9EF4-64A2A86463E7Q73453880-46385739-A86A-4B93-895E-8D6D56149D4AQ84972094-84F6BAD2-048C-4B34-B864-1BFA2A6292D9
P921
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Adefovir
@de
Adefovir
@it
Adefovir
@nl
Adefovir
@sh
Adefovir
@sl
Adefovir
@sr
Adefovir
@vi
adefovir
@en
adefovir
@fr
adefovir
@nn
type
label
Adefovir
@de
Adefovir
@it
Adefovir
@nl
Adefovir
@sh
Adefovir
@sl
Adefovir
@sr
Adefovir
@vi
adefovir
@en
adefovir
@fr
adefovir
@nn
altLabel
106941-25-7
@fr
106941-25-7
@pt-br
9-(2-(phosphonomethoxy)ethyl)adenine
@en
9-(2-phosphonylmethoxyethyl)adenine
@en
Adefovir
@en
Adefovirum
@en
Adéfovir
@en
C8H12N5O4P
@fr
C8H12N5O4P
@pt-br
Hepsera
@pt-br
prefLabel
Adefovir
@de
Adefovir
@it
Adefovir
@nl
Adefovir
@sh
Adefovir
@sl
Adefovir
@sr
Adefovir
@vi
adefovir
@en
adefovir
@fr
adefovir
@nn